The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price

Seres Therapeutics (NASDAQ:MCRB) had its price target trimmed by The Goldman Sachs Group from $1.00 to $0.75 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a sell rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Seres Therapeutics Stock Performance

Shares of Seres Therapeutics stock opened at $0.69 on Friday. The company has a market capitalization of $120.10 million, a P/E ratio of -3.00 and a beta of 2.19. The company has a fifty day moving average of $0.79 and a 200 day moving average of $0.83. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC boosted its holdings in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC boosted its holdings in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 22,250 shares during the last quarter. Avantax Advisory Services Inc. boosted its holdings in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 37,866 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 43,700 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.